ArticleEndocrine2015

Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib.

Vincenzo Marotta et al.PubMed ↗Publisher ↗

No numbers read from the abstract.